Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Finished Goods (2018 - 2025)

Protalix BioTherapeutics (PLX) has 9 years of Finished Goods data on record, last reported at $10.9 million in Q3 2025.

  • For Q3 2025, Finished Goods rose 1446.32% year-over-year to $10.9 million; the TTM value through Sep 2025 reached $10.9 million, up 1446.32%, while the annual FY2024 figure was $5.4 million, 6.28% down from the prior year.
  • Finished Goods reached $10.9 million in Q3 2025 per PLX's latest filing, up from $8.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $14.5 million in Q1 2023 and bottomed at $706000.0 in Q3 2024.
  • Average Finished Goods over 5 years is $8.5 million, with a median of $8.3 million recorded in 2022.
  • Peak YoY movement for Finished Goods: crashed 91.46% in 2024, then soared 1446.32% in 2025.
  • A 5-year view of Finished Goods shows it stood at $11.5 million in 2021, then dropped by 7.88% to $10.6 million in 2022, then crashed by 45.24% to $5.8 million in 2023, then fell by 6.28% to $5.4 million in 2024, then soared by 100.35% to $10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $10.9 million in Q3 2025, $8.6 million in Q2 2025, and $7.0 million in Q1 2025.